Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer, Eli Lilly to develop diabetes compounds
The compounds are Boehringer Ingelheim‘s two oral diabetes agents – linagliptin and BI10773 as well as Lilly‘s two basal insulin analogues – LY2605541 and LY2963016. The agreement also
The compounds are Boehringer Ingelheim‘s two oral diabetes agents – linagliptin and BI10773 as well as Lilly‘s two basal insulin analogues – LY2605541 and LY2963016. The agreement also
Merck said that the extended release formulation of Janumet is composed with sitagliptin, Januvia’s (sitagliptin) active component and metformin extended release, which is a treatment for type 2
Sinopharm, which has 16 wholly owned subsidiaries, has core business in pharmaceutical distribution, scientific research and manufacturing of medical and biotech products. Sinopharm will acquire the shares through
SamplesTogether will be powered by One Eleven’s SampleServer, e-sampling toolset used in pharmaceutical industry. SamplesTogether helps the pharmaceutical companies to optimize their sampling efforts by giving prescribers secure
The system’s workflow provides the flexibility to analyze data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over
The company has also dosed first patient in the trial. The trial is designed to investigate the safety and escalating doses of OMP-59R5 in patients who have received
Sumavel DosePro is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache. Sumavel DosePro is a pre-filled, single-use
Ranibizumab, approved in UK as a treatment for wet age-related macular degeneration (AMD) under the brand name Lucentis. Ranibizumab was developed by Genentech and Novartis. Genentech has the
In the study, the major adverse cardiac events (MACE) free survival rate in patients treated with the Genous Stent was 80.6% after one year. The single-center study investigated
Established in San Francisco’s Mission Bay life sciences hub, the new Innovation Center comprises of scientists who are working for Bayer‘s hematology research program which is focused on